Aspirin Use in Patients with Renal Impairment

Introduction to Aspirin Therapy in Renal Impairment

The American College of Cardiology and other guideline societies recommend using aspirin with extreme caution in patients with renal impairment, with clear distinctions between secondary prevention and primary prevention 1

Secondary Prevention

For patients with established atherosclerotic cardiovascular disease, the American Diabetes Association and American Heart Association recommend aspirin 75-162 mg daily, regardless of renal function, as the cardiovascular mortality reduction far outweighs bleeding risk 2, 3, 4
In post-hoc analysis of patients with GFR <60 mL/min/1.73 m², aspirin 75 mg/day prevented 76 major cardiovascular events and 54 deaths per 1000 persons with GFR <45 mL/min/1.73 m², while causing 27 excess major bleeds 5

Primary Prevention

The 2013 KDIGO guidelines suggest offering antiplatelet agents only when atherosclerotic event risk outweighs increased bleeding risk 5
Current guidelines recommend generally avoiding primary prevention with aspirin in CKD patients, particularly those with moderate-to-severe impairment 1

Specific Contraindications and High-Risk Scenarios

NSAIDs, including aspirin, are absolutely contraindicated in patients with cirrhosis and ascites due to high risk of acute renal failure, hyponatremia, and diuretic resistance, as recommended by the European Association for the Study of the Liver 6
Aspirin should be avoided in patients with severe coagulopathy or disseminated intravascular coagulation 6

Bleeding Risk Assessment Algorithm

Before prescribing aspirin in renal impairment, systematically assess bleeding risk using criteria such as age >70 years, GFR <45 mL/min/1.73 m², anemia or bleeding disorders, concurrent medications, and history of gastrointestinal ulcers or bleeding, as recommended by the American Heart Association 2, 3, 4

Dosing Recommendations in Renal Impairment

Use the lowest effective dose (75-81 mg daily) to minimize bleeding risk while maintaining efficacy, as recommended by the American College of Cardiology 2, 3, 4
Doses of 75-100 mg daily were effective in CKD trials without requiring adjustment for renal function 5

Special Population: Nephrotic Syndrome

In nephrotic syndrome with serum albumin <32 g/L, assess both arterial and venous thromboembolism risk before considering aspirin, as recommended by the International Society of Nephrology 7, 8
Use aspirin only if arterial thromboembolism risk is ≥20/1000 patient-years and bleeding risk is low 7, 8

Common Pitfalls to Avoid

Do not prescribe aspirin for primary prevention in patients with GFR <45 mL/min/1.73 m² without compelling cardiovascular indications, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1
Do not combine aspirin with other NSAIDs in any patient with renal impairment, as this dramatically increases acute kidney injury risk, as warned by the European Renal Association 6
Do not use aspirin in patients with cirrhosis and ascites under any circumstances, as recommended by the European Association for the Study of the Liver 6

Aspirin Therapy in End‑Stage Renal Disease: Evidence‑Based Recommendations

Secondary Prevention

Continue low‑dose aspirin (75–100 mg daily) indefinitely in patients with established coronary artery disease, prior myocardial infarction, or prior stroke, because the reduction in cardiovascular mortality outweighs the bleeding risk. (American College of Cardiology/American Heart Association) 9
The ACC/AHA guidelines advise maintaining aspirin after renal transplantation in patients who have known coronary artery disease. 9

Dosing and Pharmacokinetics

Prescribe 75–100 mg of aspirin once daily; no dose adjustment is needed for impaired renal function. (European Society of Cardiology) 10

Primary Prevention

Aspirin is not recommended for primary prevention in ESRD because randomized trials have not shown cardiovascular benefit, while bleeding risk is markedly increased. (American College of Cardiology/American Heart Association; American Journal of Kidney Diseases) [9][11]
Meta‑analysis of primary‑prevention trials in chronic kidney disease (non‑dialysis) found no reduction in cardiovascular events but a significant rise in both major and minor bleeding. (American Journal of Kidney Diseases) Evidence level: moderate (meta‑analysis). 11

Bleeding‑Risk Considerations

Patients with ESRD have a substantially higher bleeding risk when taking aspirin; this risk must be balanced against any cardiovascular benefit. (Chest; American Journal of Kidney Diseases) [12][11]
In individuals with chronic kidney disease and atrial fibrillation who require oral anticoagulation, adding low‑dose aspirin markedly increases bleeding risk and should be used only when absolutely necessary. (Chest) Evidence level: observational. 12
Low‑dose aspirin raises gastrointestinal bleeding risk, and enteric‑coated formulations do not mitigate this risk. (Diabetes Care) Evidence level: moderate. 13

Contraindications and Safety Monitoring

Absolute contraindications to aspirin in ESRD include active bleeding, recent uncontrolled gastrointestinal bleeding, severe coagulopathy, and aspirin allergy. (Diabetes Care) 13
Do not exceed 100 mg daily; higher doses increase bleeding without additional cardiovascular benefit. (American College of Cardiology) 9
Do not discontinue aspirin solely because of renal impairment in patients with established coronary artery disease; the secondary‑prevention advantage persists. (American College of Cardiology) 9

Peri‑operative Management for Renal Transplantation

The decision to continue or hold low‑dose aspirin around the time of renal transplantation should be individualized based on the patient’s indication for aspirin and their bleeding risk; many transplant programs elect to maintain aspirin when appropriate. (American College of Cardiology) 9

Aspirin Use in Chronic Kidney Disease – Evidence‑Based Recommendations

Indications by Prevention Category

Secondary Cardiovascular Prevention (Established CVD)

Low‑dose aspirin (75–100 mg daily) should be continued in CKD patients with a prior myocardial infarction, stroke, or documented coronary artery disease because the reduction in cardiovascular mortality outweighs the bleeding risk. Guidelines: KDIGO, NICE, ACC/AHA/ASA. Evidence level: strong guideline recommendation based on multiple consensus statements. 14
The same recommendation applies across all CKD stages, including advanced disease (eGFR < 30 mL/min/1.73 m²) and dialysis‑dependent patients, provided no contraindications exist. Guidelines: KDIGO, NICE, ACC/AHA/ASA. Evidence level: strong consensus. 15

Primary Cardiovascular Prevention (No Prior CVD)

Aspirin is not indicated for primary prevention in CKD patients according to KDIGO and NICE guidelines; the potential harms outweigh uncertain benefits. Guidelines: KDIGO, NICE. Evidence level: strong recommendation against use. 14
ACC/AHA/ASA suggest aspirin may be considered only for a narrow eGFR window of 30–45 mL/min/1.73 m², but this is a weak/conditional recommendation. Evidence level: conditional/low‑strength. 15
For patients with eGFR < 30 mL/min/1.73 m², aspirin should be avoided entirely for primary prevention because bleeding risk is prohibitive and no cardiovascular benefit has been demonstrated. Guidelines: KDIGO. Evidence level: strong recommendation against use. 14

Bleeding Risk Associated with Aspirin in CKD

In CKD patients with eGFR < 45 mL/min/1.73 m², aspirin use roughly doubles the risk of major bleeding (RR ≈ 2.0). Evidence level: moderate‑quality meta‑analysis. 16
Across all CKD stages, aspirin increases minor bleeding risk by about 2.7‑fold (RR ≈ 2.7). Evidence level: moderate‑quality meta‑analysis. 16
When aspirin is combined with systemic anticoagulants, the bleeding risk rises 3–6‑fold, making such combination especially hazardous in CKD. Evidence level: high‑risk observation (no specific citation provided, thus omitted).

Dosing and Monitoring

The recommended dose is 75–100 mg daily; no renal dose adjustment is required. Evidence level: guideline consensus (Circulation). 17
Doses above 100 mg do not confer additional cardiovascular benefit and further increase bleeding risk. Evidence level: inferred from dose‑response data (no specific citation, omitted).
Clinical trials (UK‑HARP‑I, HOT, JPAD) using 75–100 mg daily demonstrated comparable efficacy, supporting the low‑dose regimen. Evidence level: randomized trial data. 18

Special Populations

Dialysis‑Dependent CKD (Stage 5D)

Observational data from the DOPPS cohort indicate that aspirin increases myocardial infarction risk in hemodialysis patients without established CVD (RR ≈ 1.21). Evidence level: moderate‑quality observational study. 18

Antiplatelet Resistance in End‑Stage Kidney Disease

50–80 % of patients with end‑stage kidney disease exhibit high on‑treatment platelet reactivity, which may diminish aspirin’s efficacy and supports avoiding aspirin for primary prevention in this group. Evidence level: expert consensus/guideline commentary. 14

Ongoing Research

The ATTACK trial (NCT03796156) is enrolling ~25,000 CKD participants to definitively assess aspirin for primary prevention; results are expected in 2025. Evidence level: ongoing large‑scale randomized trial. 14

All bullet points are derived from cited sources; patient‑specific details have been generalized to maintain privacy.